AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP issued a solicitation reminding Aardvark Therapeutics investors of a securities fraud class action with an October 13, 2026 lead plaintiff deadline. The complaint alleges Aardvark misled investors about the safety profile and prospects of its ARD-101 drug candidate, covering purchasers from the February 13, 2025 IPO through May 14, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.